This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Neurology				
Alzheimer's disease (AD)	Glycogen dependent kinase 3 (GSK3)	<p>Mouse studies suggest inhibiting GSK3 could help to treat AD. In a mouse model of aggressive AD, animals showed hyperactive GSK3 and developed massive cerebral β-amyloid ($A\beta$) loads, memory deficits and neuronal loss. Nasal delivery of the GSK3 inhibitor L803-mt decreased $A\beta$ deposits and increased cognitive function compared with no treatment. Next steps include completing preclinical safety and toxicity studies.</p> <p>SciBX 5(48); doi:10.1038/scibx.2012.1262 Published online Dec. 13, 2012</p>	Patented by Ramot at Tel Aviv University; available for licensing	<p>Avrahami, L. <i>et al. J. Biol. Chem.</i>; published online Nov. 15, 2012; doi:10.1074/jbc.M112.409250 Contact: Hagit Eldar-Finkelman, Tel Aviv University, Tel Aviv, Israel e-mail: heldar@post.tau.ac.il Contact: Dan Frenkel, same affiliation as above e-mail: dannyf34@gmail.com</p>